[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-370523-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-370523-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","development-and-application-of-a-whole-transcriptome-sequencing-assay-for-the-detection-of-gene-fusions-in-clinical-cancer-specimens","Development and application of a whole transcriptome sequencing assay for the detection of gene fusions in clinical cancer specimens","","Gene fusions drive cancer and require rapid, accurate identification to support clinical decisions, yet the performance of whole transcriptome sequencing (WTS) for fusion detection has remained insufficiently characterized. A novel WTS-based assay was developed to detect gene fusions and alterations including MET exon 14 skipping and EGFR VIII in clinical specimens. Using defined RNA quality and input thresholds, the assay showed 98.4% sensitivity, 100% specificity, and strong repeatability and reproducibility, with additional insights into actionable and non-actionable fusion landscapes across cancers.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/development-and-application-of-a-whole-transcriptome-sequencing-assay-for-the-detection-of-gene-fusions-in-clinical-cancer-specimens/370523/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/development-and-application-of-a-whole-transcriptome-sequencing-assay-for-the-detection-of-gene-fusions-in-clinical-cancer-specimens/370523.png","ImageObject",300,407,{"name":42,"@type":43},"WPS_1786070896","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-12","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why is gene fusion detection important for clinical cancer decisions?","Question",{"text":63,"@type":64},"Gene fusions are key drivers of cancer and can guide clinical treatment choices. Accurate detection is needed to support decisions based on actionable alterations.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What assay was developed in this study and what alterations did it target?",{"text":68,"@type":64},"The study developed a WTS-based assay to detect gene fusions, including MET exon 14 skipping and EGFR VIII alterations, in clinical samples.",{"name":70,"@type":61,"acceptedAnswer":71},"What performance did the WTS assay achieve for known and fusion-negative samples?",{"text":72,"@type":64},"The assay identified 62 out of 63 known gene fusions with 98.4% sensitivity. Specificity was 100%, with no fusions detected in 21 fusion-negative samples.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},370523,1790846857,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},549768072016,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Zhao et al. BMC Cancer (2025) 25:842 BMC Cancer  \n[https://doi.org/10.1186/s12885-025-14186-w](https://doi.org/10.1186/s12885-025-14186-w)  \nRESEARCH Open Access  \nDevelopment and application of a whole transcriptome sequencing assay for the detection of gene fusions in clinical cancer specimens  \nSongchen Zhao 1, Xinhua Du2, Yan Zhang2, Jing Bai2,3, Lu Meng2, Xuefei Li4, Jiaxin Ma2, HeYu Sheng2, Xiaorui Fu2, Yanfang Guan2, Yuting Yi2, Ling Yang2, Xuefeng Xia2, Xin Yi2, Xinxin Tan5,6* and Caicun Zhou7*  \nAbstract  \nBackground Gene fusions are an important driver of cancer and require rapid and accurate detection to guide clinical decisions. However, the performance characteristics of whole transcriptome sequencing (WTS) for the detection of gene fusions have not been thoroughly investigated.  \nMethods We developed a novel WTS-based assay for the detection of gene fusions, MET exon 14 skipping and EGFR VIII alterations in clinical samples.  \nResults We defined a DV200 value ≥ 30% as the threshold for RNA degradation, RNA input, fusion expression and number of mapped reads greater than 100 ng, 40 copies/ng and 80 Mb for optimal sensitivity ofthe WTS assay. Our assay successfully identified 62 out of 63 known gene fusions, achieving a sensitivity of 98 .4% . The specificity of the assay was 100%, as no fusions were detected in the 21 fusion-negative samples. Good repeatability and reproducibility were observed in replicates, except for the TPM3::NTRK1 fusion, which was expressed below the threshold. Of all fusions identified in 101 NSCLC samples, 68 . 9%(20/29) were potentially actionable, compared to 20% in pan-cancer samples. In addition to actionable fusions, we also identified many fusions with potential diagnostic and prognostic value in pan-cancer.  \nConclusions We have developed a novel WTS assay with high sensitivity, specificity, repeatability and reproducibility. This assay can identify potentially actionable gene fusions and provides valuable insights into the fusion landscape in various cancers, which may help guide treatment decisions and aid in diagnosis and prognosis.  \nKeywords Gene fusions, WTS assay, Actionable fusions, Cancer specimens  \n*Correspondence: Xinxin Tan [tanxx@geneplus.org.cn](tanxx@geneplus.org.cn)[ ](tanxx@geneplus.org.cn)Caicun Zhou [caicunzhoudr@163.com](caicunzhoudr@163.com)  \n1Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China  \n2Geneplus-Beijing Institute, Beijing, China  \n3College of Future Technology, Peking University, Beijing, China 4Department of Lung Cancer and Immunology, Tongji University Affiliated Shanghai Pulmonary Hospital, Shanghai, China 5Geneplus-Shenzhen Clinical Laboratory, Shenzhen, Guangdong, China 6Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, Hunan, China  \n7Department of Medical Oncology, Shanghai East Hospital, Shanghai, China  \n© The Author(s) 2025. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creati](http://creati)[vecommons.org/l](vecommons.org/l)icenses/","cbCaigK0o9RId1co","https://ap.wps.com/l/cbCaigK0o9RId1co","pdf",3052625,13,"English","# Abstract\n# Background\n# Methods\n# Results\n# Conclusions\n# Introduction","[{\"question\":\"Why is gene fusion detection important for clinical cancer decisions?\",\"answer\":\"Gene fusions are key drivers of cancer and can guide clinical treatment choices. Accurate detection is needed to support decisions based on actionable alterations.\"},{\"question\":\"What assay was developed in this study and what alterations did it target?\",\"answer\":\"The study developed a WTS-based assay to detect gene fusions, including MET exon 14 skipping and EGFR VIII alterations, in clinical samples.\"},{\"question\":\"What performance did the WTS assay achieve for known and fusion-negative samples?\",\"answer\":\"The assay identified 62 out of 63 known gene fusions with 98.4% sensitivity. Specificity was 100%, with no fusions detected in 21 fusion-negative samples.\"}]","Development and application of a whole transcriptome sequencing assay for the detection of gene fusions in clinical cancer specimens | PDF",1790188957,33,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0d75941b77866f362fed573225e528ff.webp",983,1310,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ce27f38785b50d3de6109cbd98623f87.webp",982,1309,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1379c91731e1e178b2e94feed663178d.webp",981,1308,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7c1ae808eba98bec269c0fe3f5e78ed4.webp",980,1306]